These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 17931154)

  • 1. IC31 and IC30, novel types of vaccine adjuvant based on peptide delivery systems.
    Lingnau K; Riedl K; von Gabain A
    Expert Rev Vaccines; 2007 Oct; 6(5):741-6. PubMed ID: 17931154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens.
    Perrie Y; Mohammed AR; Kirby DJ; McNeil SE; Bramwell VW
    Int J Pharm; 2008 Dec; 364(2):272-80. PubMed ID: 18555624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant.
    Garçon N; Heppner DG; Cohen J
    Expert Rev Vaccines; 2003 Apr; 2(2):231-8. PubMed ID: 12899574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influenza virosomes as a vaccine adjuvant and carrier system.
    Moser C; Amacker M; Zurbriggen R
    Expert Rev Vaccines; 2011 Apr; 10(4):437-46. PubMed ID: 21506642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TLR9 agonists as adjuvants for prophylactic and therapeutic vaccines.
    Daubenberger CA
    Curr Opin Mol Ther; 2007 Feb; 9(1):45-52. PubMed ID: 17330401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The path to a successful vaccine adjuvant--'the long and winding road'.
    O'Hagan DT; De Gregorio E
    Drug Discov Today; 2009 Jun; 14(11-12):541-51. PubMed ID: 19508916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cationic liposomes as vaccine adjuvants.
    Christensen D; Korsholm KS; Andersen P; Agger EM
    Expert Rev Vaccines; 2011 Apr; 10(4):513-21. PubMed ID: 21506648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaxfectin: a versatile adjuvant for plasmid DNA- and protein-based vaccines.
    Sullivan SM; Doukas J; Hartikka J; Smith L; Rolland A
    Expert Opin Drug Deliv; 2010 Dec; 7(12):1433-46. PubMed ID: 21118032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.
    Jasani B; Navabi H; Adams M
    Vaccine; 2009 May; 27(25-26):3401-4. PubMed ID: 19200817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bacterial ghosts as adjuvant particles.
    Riedmann EM; Kyd JM; Cripps AW; Lubitz W
    Expert Rev Vaccines; 2007 Apr; 6(2):241-53. PubMed ID: 17408373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microparticle-based technologies for vaccines.
    O'Hagan DT; Singh M; Ulmer JB
    Methods; 2006 Sep; 40(1):10-9. PubMed ID: 16997709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The novel adjuvant combination of CpG ODN, indolicidin and polyphosphazene induces potent antibody- and cell-mediated immune responses in mice.
    Kovacs-Nolan J; Latimer L; Landi A; Jenssen H; Hancock RE; Babiuk LA; van Drunen Littel-van den Hurk S
    Vaccine; 2009 Mar; 27(14):2055-64. PubMed ID: 19428830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poly(gamma-glutamic acid) nanoparticles as an efficient antigen delivery and adjuvant system: potential for an AIDS vaccine.
    Wang X; Uto T; Akagi T; Akashi M; Baba M
    J Med Virol; 2008 Jan; 80(1):11-9. PubMed ID: 18041033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IC31, a two-component novel adjuvant mixed with a conjugate vaccine enhances protective immunity against pneumococcal disease in neonatal mice.
    Olafsdottir TA; Lingnau K; Nagy E; Jonsdottir I
    Scand J Immunol; 2009 Mar; 69(3):194-202. PubMed ID: 19281531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists.
    Vollmer J; Krieg AM
    Adv Drug Deliv Rev; 2009 Mar; 61(3):195-204. PubMed ID: 19211030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in transcutaneous vaccine delivery: do all ways lead to Rome?
    Bal SM; Ding Z; van Riet E; Jiskoot W; Bouwstra JA
    J Control Release; 2010 Dec; 148(3):266-82. PubMed ID: 20869998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resiquimod and other immune response modifiers as vaccine adjuvants.
    Tomai MA; Miller RL; Lipson KE; Kieper WC; Zarraga IE; Vasilakos JP
    Expert Rev Vaccines; 2007 Oct; 6(5):835-47. PubMed ID: 17931162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunization with recombinant Brucella species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against Brucella abortus infection.
    Pasquevich KA; Estein SM; García Samartino C; Zwerdling A; Coria LM; Barrionuevo P; Fossati CA; Giambartolomei GH; Cassataro J
    Infect Immun; 2009 Jan; 77(1):436-45. PubMed ID: 18981242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
    Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
    Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adult-like anti-mycobacterial T cell and in vivo dendritic cell responses following neonatal immunization with Ag85B-ESAT-6 in the IC31 adjuvant.
    Kamath AT; Rochat AF; Valenti MP; Agger EM; Lingnau K; Andersen P; Lambert PH; Siegrist CA
    PLoS One; 2008; 3(11):e3683. PubMed ID: 18997860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.